Cisplatin and Thromboembolic Events in Cervical Cancer
Author Information
Author(s): Anders Jon C, Grigsby Perry W, Singh Anurag K
Hypothesis
Is the risk of life-threatening thromboembolic events higher in cervical cancer patients receiving cisplatin chemotherapy without erythropoietin than reported in trials?
Conclusion
The incidence of cardiovascular toxicity in patients receiving cisplatin chemotherapy without erythropoietin is significantly higher than previously reported in prospective trials.
Supporting Evidence
- Only 0.1% of patients in large trials experienced severe cardiovascular toxicities.
- In a recent study, 4.7% of patients developed serious cardiovascular toxicity.
- The difference in reported toxicity rates suggests underreporting in trials.
Takeaway
This study found that more cervical cancer patients on cisplatin had serious blood clots than doctors thought, suggesting they need to pay more attention to this risk.
Methodology
A review of several prospective trials and a retrospective analysis of patient data.
Potential Biases
Potential underreporting of thromboembolic events in prospective trials.
Limitations
The study relies on retrospective data and may not capture all cases of thromboembolic events.
Participant Demographics
Patients with cervical cancer receiving cisplatin chemotherapy.
Statistical Information
P-Value
< 0.00001
Statistical Significance
p < 0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website